Area of research
Hematology · Cancer Research
Research interest
Research interests include Multiple Myeloma Research and Treatments, Cancer Genomics and Diagnostics, Protein Degradation and Inhibitors, and Acute Myeloid Leukemia Research.
Tocilizumab prophylaxis for patients with multiple myeloma treated with bispecific antibodies
Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma
Temporal genomic dynamics shape clinical trajectory in multiple myeloma
Randomized, multi-center study of carfilzomib, lenalidomide, and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM): The ADVANCE clinical trial.
Mutagenic Impact and Evolutionary Influence of Chemoradiotherapy in Hematologic Malignancies
The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma
Tocilizumab Prophylaxis for Patients with Relapsed or Refractory Multiple Myeloma Treated with Teclistamab, Elranatamab or Talquetamab
CD38 biallelic loss is a recurrent mechanism of resistance to anti-CD38 antibodies in multiple myeloma
Functional variant rs9344 at 11q13.3 regulates CCND1 expression in multiple myeloma with t(11;14)
Temporal Genomic Dynamics Shape Clinical Trajectory in Multiple Myeloma
Tocilizumab Prophylaxis for Patients Treated with Teclistamab: A Single-Center Experience